BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Franzin R, Netti GS, Spadaccino F, Porta C, Gesualdo L, Stallone G, Castellano G, Ranieri E. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand? Front Immunol 2020;11:574271. [PMID: 33162990 DOI: 10.3389/fimmu.2020.574271] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Won Min J, Uk Lim J. Review: A narrative review of predicting acute kidney injury induced by immune checkpoint inhibitors and the appropriate usage of ICI in chronic kidney disease patients. Seminars in Oncology 2022. [DOI: 10.1053/j.seminoncol.2022.01.012] [Reference Citation Analysis]
2 Gulikers JL, Croes S, Schreurs MJW, Litjens EJR, Aarts MJB, van Geel RMJM. Nivolumab exposure in a hemodialysis patient with metastatic melanoma. Melanoma Res 2021;31:579-81. [PMID: 34433199 DOI: 10.1097/CMR.0000000000000775] [Reference Citation Analysis]
3 Ackerman RS, Muncey AR, Aldawoodi NN, Kotha R, Getting REG. Cancer Immunotherapies: What the Perioperative Physician Needs to Know. Curr Oncol Rep 2022. [PMID: 35141856 DOI: 10.1007/s11912-022-01202-6] [Reference Citation Analysis]
4 Kamyshova ES, Bobkova IN, Sekacheva MI. Kidney injury associated with antitumor therapy: focus on the adverse events of modern immuno-oncological drugs. Terapevticheskii arkhiv 2021;93:649-60. [DOI: 10.26442/00403660.2021.06.200860] [Reference Citation Analysis]
5 Tinawi M, Bastani B. Nephrotoxicity of Immune Checkpoint Inhibitors: Acute Kidney Injury and Beyond. Cureus 2020;12:e12204. [PMID: 33489613 DOI: 10.7759/cureus.12204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Fanciulli G, Di Molfetta S, Dotto A, Florio T, Feola T, Colao A, Faggiano A; NIKE Group. Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management. Front Endocrinol (Lausanne) 2021;12:700806. [PMID: 34220723 DOI: 10.3389/fendo.2021.700806] [Reference Citation Analysis]
7 Märkl F, Huynh D, Endres S, Kobold S. Utilizing chemokines in cancer immunotherapy. Trends in Cancer 2022. [DOI: 10.1016/j.trecan.2022.04.001] [Reference Citation Analysis]
8 Fanciulli G, Di Molfetta S, Dotto A, Florio T, Feola T, Rubino M, de Cicco F, Colao A, Faggiano A, Nike Group. Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks. J Clin Med 2020;10:E88. [PMID: 33383673 DOI: 10.3390/jcm10010088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
9 Mocan-Hognogi DL, Trancǎ S, Farcaş AD, Mocan-Hognogi RF, Pârvu AV, Bojan AS. Immune Checkpoint Inhibitors and the Heart. Front Cardiovasc Med 2021;8:726426. [PMID: 34660728 DOI: 10.3389/fcvm.2021.726426] [Reference Citation Analysis]
10 Belliere J, Mazieres J, Meyer N, Chebane L, Despas F. Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies. Diagnostics (Basel) 2021;11:1187. [PMID: 34208848 DOI: 10.3390/diagnostics11071187] [Reference Citation Analysis]
11 Kwiatkowska E, Domański L, Dziedziejko V, Kajdy A, Stefańska K, Kwiatkowski S. The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage. Int J Mol Sci 2021;22:6109. [PMID: 34204029 DOI: 10.3390/ijms22116109] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Orte Cano C, Van Meerhaeghe T, Tannous J, Lienard D, Van Gestel D, Cuylits N, Luce S, Carlot S, Le Moine A, Aspeslagh S, Del Marmol V. Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab. J Eur Acad Dermatol Venereol 2022;36 Suppl 1:53-8. [PMID: 34855244 DOI: 10.1111/jdv.17658] [Reference Citation Analysis]
13 Pesola G, Murianni V, Rebuzzi SE, Banna GL, Cerbone L, Catalano F, Borea R, Gandini A, Cremante M, Puglisi S, Trovato F, Fornarini G. Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse events: a case report. Immunotherapy 2021;13:1379-86. [PMID: 34743545 DOI: 10.2217/imt-2021-0085] [Reference Citation Analysis]
14 Yu S, Li X, Zhang J, Wu S. Development of a Novel Immune Infiltration-Based Gene Signature to Predict Prognosis and Immunotherapy Response of Patients With Cervical Cancer. Front Immunol 2021;12:709493. [PMID: 34539641 DOI: 10.3389/fimmu.2021.709493] [Reference Citation Analysis]
15 Tao L, Zhang H, An G, Lan H, Xu Y, Ge Y, Yao J. Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:739263. [PMID: 34722290 DOI: 10.3389/fonc.2021.739263] [Reference Citation Analysis]
16 Niedbała M, Malarz K, Sharma G, Kramer-Marek G, Kaspera W. Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations. Onco Targets Ther 2022;15:437-68. [PMID: 35509452 DOI: 10.2147/OTT.S215997] [Reference Citation Analysis]
17 Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail 2021. [PMID: 34196077 DOI: 10.1002/ejhf.2289] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Liu S, Zhao J, Wang F. Acute kidney injury in cancer patients. Clin Exp Nephrol 2021. [PMID: 34499266 DOI: 10.1007/s10157-021-02131-7] [Reference Citation Analysis]